Ravi K. Amaravadi
Associate Director, Translational Research, Abramson Cancer Center · Penn Medicine
Credentials: · · ·
History
PresentUPenn/Wistar Skin Cancer SPORE · Penn Medicine
- Present
Research
Guidelines for the use and interpretation of assays for monitoring autophagy
Autophagy · 2012 · 2,918 citations
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Nature · 2015 · 2,020 citations
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
New England Journal of Medicine · 2012 · 1,763 citations
74 papers
61 papers
56 papers
54 papers
28 papers · 22 as a fellow
23 papers
17 papers
13 papers
Grants
- 2022–2027
Resistance Mechanisms to Autophagy-Modulating Therapies
National Cancer Institute · R01
Contact PI · $3.2M · University of Pennsylvania
- 2021–2026
- 1997–2025
Abramson Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $739.7K · University of Pennsylvania
- 2008–2025
Targeted Therapies in Melanoma
National Cancer Institute · P01
Project lead · $2.3M · Wistar Institute
Clinical trials
- 2026–2029
PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma
Principal investigator · Not yet recruiting · Early phase 1
Abramson Cancer Center at Penn Medicine
- 2021–2024
Principal investigator · Terminated · Phase 2
ECOG-ACRIN Cancer Research Group
- 2020–2027
Principal investigator · Active not recruiting · Phase 1, Phase 2
Ravi Amaravadi, MD
- 2020
The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)
Principal investigator · Terminated · Phase 2
Ravi Amaravadi, MD